3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]-2,3-difluoroanilino]methyl]-2-[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[[N-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxycarbonyl]-2,3-difluoroanilino]methyl]-2-[(1S)-2-(3,5-dichloro-1-oxidopyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]benzoic acid
• 化学式: C37H35Cl2F2N3O7
• 分子量: 742.6
• InChiKey: NWVJJFQQSILBLQ-JQJBXXCASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  51
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  114
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• NOVEL COMPOUNDS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20140155427A1

  公开（公告）日：2014-06-05

  Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

  本文描述的化合物(I)的公式是磷酸二酯酶4（PDE4）酶的抑制剂和肌动蛋白M3受体拮抗剂，可用于预防和/或治疗以气道阻塞为特征的呼吸道疾病。
• Receptor-Type Kinase Modulators and Methods of Use
  申请人：SYMPHONY EVOLUTION, INC.

  公开号：US20140155418A1

  公开（公告）日：2014-06-05

  The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.

  本发明提供了用于调节受体激酶活性的化合物，特别是ephrin和EGFR，并利用这些化合物和其制备的药物组合物治疗受受体激酶活性介导的疾病的方法。由受体激酶活性介导的疾病包括但不限于部分由细胞增殖异常水平（即肿瘤生长）、程序性细胞死亡（凋亡）、细胞迁移和侵袭以及与肿瘤生长相关的血管生成所特征化的疾病。本发明的化合物包括“光谱选择性”激酶调节剂，抑制、调节和/或调节受体型酪氨酸激酶亚家族的信号转导，包括ephrin和EGFR。
• US9199980B2
  申请人：——

  公开号：US9199980B2

  公开（公告）日：2015-12-01
• US9359332B2
  申请人：——

  公开号：US9359332B2

  公开（公告）日：2016-06-07